Tumor cells are morphologically different from normal cells. In this situation, we proposed that plectin, one of the intermediate filament associated proteins, might play some special roles in the tumorigenesis. Plectin exhibits a wide distribution spectrum among various tissues; however, it is scarcely investigated in tumor tissues including colorectal adenocarcinoma. In this study, we searched the plectin expression in 25 cases of colorectal adenocarcinoma and 10 cases of tubular adenoma with focal adenocarcinoma by immunohistochemical method. The results reveal that plectin is up-regulated in colorectal adenocarcinoma as well as in bizarre glands and locally invasive tumor nests in tubular adenoma, compared with normal colorectal mucosa. Over-expression of plectin in locally invasive tumor nests might help us in diagnosis of distinguish microinvasive foci from normal glands. The bizarre glands in adenoma might be precancerous lesions since the expression of plectin in them was identical to that of adenocarcinoma but in contrast to that of normal glands. The overexpression of plectin might affect the organization of cytoskeleton, which might further cause tumorigenesis and morphological change of colorectal epithelial cells.

Download full-text PDF

Source

Publication Analysis

Top Keywords

colorectal adenocarcinoma
12
plectin
8
plectin expression
8
tubular adenoma
8
bizarre glands
8
locally invasive
8
invasive tumor
8
tumor nests
8
normal glands
8
colorectal
6

Similar Publications

Introduction: Previous research has demonstrated that after neoadjuvant therapy for rectal cancer, the sensitivity of magnetic resonance complete response (mrCR) for detecting pathologic complete response (pCR) in the surgical specimen ranges from 74 to 94%. Patient and provider interest in nonoperative management of rectal cancer that responds favorably to neoadjuvant therapy has grown, necessitating stronger evidence for how well radiographic complete response truly predicts pCR. We sought to determine the current association between mrCR and pCR in locally advanced rectal cancer.

View Article and Find Full Text PDF

Design, Structure Optimization, and Preclinical Characterization of JAB-21822, a Covalent Inhibitor of KRAS.

J Med Chem

January 2025

Chief executive officer, Jacobio Pharmaceuticals Group Co., Ltd., Beijing100176, P. R. China.

KRAS is the most frequently mutated driver oncogene in human cancer, and KRAS mutation is commonly found in non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC). Inhibitors that covalently modify the mutated codon 12 cysteine have completed proof-of-concept studies in the clinic. Here, we describe structure-based design and cocrystal-aided drug optimization of a series of compounds with the 1,8-naphthyridine-3-carbonitrile scaffold.

View Article and Find Full Text PDF

Background And Purpose: Genome-wide methylation studies have significantly advanced our understanding of colorectal adenocarcinoma progression and biomarker discovery. Aberrant DNA methylation plays a crucial role in gene expression regulation during cancer transformation, highlighting the need to identify differentially methylated regions (DMRs) as potential diagnostic and therapeutic markers. However, an integrated resource to explore and validate methylation alterations across colorectal cancer stages has been lacking.

View Article and Find Full Text PDF

Unlabelled: Immune escape is a critical hallmark of cancer progression and underlies resistance to multiple immunotherapies. However, it remains unclear when the genetic events associated with immune escape occur during cancer development. Here, we integrate functional genomics studies of immunomodulatory genes with a tumor evolution reconstruction approach to infer the evolution of immune escape across 38 cancer types from the Pan-Cancer Analysis of Whole Genomes dataset.

View Article and Find Full Text PDF

Background: Mucinous adenocarcinoma is a rare type of colorectal cancer (CRC) associated with poor prognosis, particularly when it includes signet ring cell components. Furthermore, its rate of microsatellite instability-high (MSI-H) is significantly higher compared to non-mucinous adenocarcinoma. Immunotherapy has emerged as the standard treatment for MSI-H metastatic CRC (mCRC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!